Market Overview:
The global common cancer-associated antigens (CAAs) vaccine market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising awareness about CAAs vaccines, and technological advancements in the field of vaccine development. Based on type, the global common cancer-associated antigens (CAAs) vaccine market is segmented into tecemotide, astuprotimut-R, tertomotide, nelipepimut-S and others. Based on application, the market is segmented into pediatrics and adults. Geographically, the global common cancer-associated antigens (CAAs) vaccine market is segmented into North America, Latin America Europe Asia Pacific and Middle East & Africa.
 Vaccine Industry Outlook.svg)
Product Definition:
The Common Cancer-associated Antigens (CAAs) Vaccine is used to help prevent certain types of cancer. The vaccine works by helping the body build immunity against common cancer-associated antigens. These antigens are proteins that are commonly found on the surface of many types of cancer cells. The vaccine can help protect against cancers such as colorectal cancer, ovarian cancer, and prostate cancer.
Tecemotide:
The global tecemotide market size was valued at USD 31.0 million in 2018 and is expected to grow at a compound annual growth rate (CAGR) of 8.5% from 2019 to 2023. Factors, such as rising prevalence of cancer, increasing focus on immunization against tumor-associated antigens, and the presence of a strong product pipeline are anticipated to drive the market over the forecast period.
Astuprotimut-R:
Astuprotimut-R is a new vaccine developed by GlaxoSmithKline (GSK) and the University of Queensland. Astuprotimut-R is an attenuated live, oral vaccine virus that replicates itself in the cells of the immune system. The research study was published on 27th September 2015 in the open access journal “PLOS ONE”.
Application Insights:
Based on the application, the global common cancer-associated antigens (CAAs) vaccine market is segmented into adults and pediatric patients. The adult segment held a larger share in 2017 owing to the rising prevalence of various types of cancers, such as lung, breast and colorectal cancer. According to data published by WHO in 2018 regarding cancer incidence worldwide, it was estimated that around 1 in 6 women and 1 in 5 men are expected to develop some form of cancer during their lifetime. Thus, increasing incidences of these types of cancers across the globe is anticipated to fuel demand for CAA vaccines over the forecast period.
The growing awareness about immunization against infectious diseases coupled with rising incidences caused by novel pathogens is anticipated to drive growth among pediatric patients over forecast period.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, increasing focus on cancer immunotherapy, and availability of effective treatment methods for various types of cancers. Moreover, high adoption rate for new vaccination technologies is also expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising awareness about CAAs vaccine among individuals as well as healthcare professionals in this region. Furthermore, growing target population base due to low cost burden and improved access due tp favorable government initiatives will support regional market expansion during the same period (2018-2030).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the global common cancer-associated antigens (CAAs) vaccine market. According to a study by the World Health Organization (WHO), an estimated 14 million new cases of cancer were diagnosed in 2012, and this number is expected to rise to 24 million by 2030. This growing prevalence of cancer is fuelling demand for common CAAs vaccines, which can help prevent or treat the disease.
- Rising awareness about preventive measures: There has been a rising awareness among people about preventive measures against various types of cancers in recent years. This is boosting demand for common CAAs vaccines, as they can help reduce the risk of developing certain types of cancers.
- Technological advancements: The development and commercialization of novel technologies such as next-generation sequencing (NGS) and monoclonal antibodies (mAbs) are aiding in identification and characterizationof new CAAs targets, which is driving growth prospects forthe globalcommon CAAvaccine market . Additionally, technological advancements are helping manufacturers develop more efficacious and safe vaccines that can be used to prevent or treat different types oftumors .
Scope Of The Report
Report Attributes
Report Details
Report Title
Common Cancer-associated Antigens (CAAs) Vaccine Market Research Report
By Type
Tecemotide, Astuprotimut-R, Tertomotide, Nelipepimut-S, Others
By Application
Pediatrics, Adults
By Companies
Seattle Genetics, Merck Serono, Merck KGaA, GlaxoSmithKline, KAEL-GemVax, SELLAS Life Sciences, Celldex, Immatics Biotechnologies
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
134
Number of Tables & Figures
94
Customization Available
Yes, the report can be customized as per your need.
Global Common Cancer-associated Antigens (CAAs) Vaccine Market Report Segments:
The global Common Cancer-associated Antigens (CAAs) Vaccine market is segmented on the basis of:
Types
Tecemotide, Astuprotimut-R, Tertomotide, Nelipepimut-S, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pediatrics, Adults
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Seattle Genetics
- Merck Serono
- Merck KGaA
- GlaxoSmithKline
- KAEL-GemVax
- SELLAS Life Sciences
- Celldex
- Immatics Biotechnologies
 Vaccine Market Overview.svg)
Highlights of The Common Cancer-associated Antigens (CAAs) Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tecemotide
- Astuprotimut-R
- Tertomotide
- Nelipepimut-S
- Others
- By Application:
- Pediatrics
- Adults
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Common Cancer-associated Antigens (CAAs) Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Vaccine Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
CAAs are a group of proteins that are commonly associated with cancer. There is currently no CAAs vaccine available.
Some of the major companies in the common cancer-associated antigens (caas) vaccine market are Seattle Genetics, Merck Serono, Merck KGaA, GlaxoSmithKline, KAEL-GemVax, SELLAS Life Sciences, Celldex, Immatics Biotechnologies.
The common cancer-associated antigens (caas) vaccine market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Common Cancer-associated Antigens (CAAs) Vaccine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Common Cancer-associated Antigens (CAAs) Vaccine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Common Cancer-associated Antigens (CAAs) Vaccine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Common Cancer-associated Antigens (CAAs) Vaccine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size & Forecast, 2018-2028
4.5.1 Common Cancer-associated Antigens (CAAs) Vaccine Market Size and Y-o-Y Growth
4.5.2 Common Cancer-associated Antigens (CAAs) Vaccine Market Absolute $ Opportunity
Chapter 5 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Type
5.2.1 Tecemotide
5.2.2 Astuprotimut-R
5.2.3 Tertomotide
5.2.4 Nelipepimut-S
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Applications
6.2.1 Pediatrics
6.2.2 Adults
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Common Cancer-associated Antigens (CAAs) Vaccine Analysis and Forecast
9.1 Introduction
9.2 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Type
9.6.1 Tecemotide
9.6.2 Astuprotimut-R
9.6.3 Tertomotide
9.6.4 Nelipepimut-S
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Applications
9.10.1 Pediatrics
9.10.2 Adults
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Common Cancer-associated Antigens (CAAs) Vaccine Analysis and Forecast
10.1 Introduction
10.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Type
10.6.1 Tecemotide
10.6.2 Astuprotimut-R
10.6.3 Tertomotide
10.6.4 Nelipepimut-S
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Applications
10.10.1 Pediatrics
10.10.2 Adults
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Type
11.6.1 Tecemotide
11.6.2 Astuprotimut-R
11.6.3 Tertomotide
11.6.4 Nelipepimut-S
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Applications
11.10.1 Pediatrics
11.10.2 Adults
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Analysis and Forecast
12.1 Introduction
12.2 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Type
12.6.1 Tecemotide
12.6.2 Astuprotimut-R
12.6.3 Tertomotide
12.6.4 Nelipepimut-S
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Applications
12.10.1 Pediatrics
12.10.2 Adults
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Common Cancer-associated Antigens (CAAs) Vaccine Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Type
13.6.1 Tecemotide
13.6.2 Astuprotimut-R
13.6.3 Tertomotide
13.6.4 Nelipepimut-S
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Common Cancer-associated Antigens (CAAs) Vaccine Market Size Forecast by Applications
13.10.1 Pediatrics
13.10.2 Adults
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Common Cancer-associated Antigens (CAAs) Vaccine Market: Competitive Dashboard
14.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Seattle Genetics
14.3.2 Merck Serono
14.3.3 Merck KGaA
14.3.4 GlaxoSmithKline
14.3.5 KAEL-GemVax
14.3.6 SELLAS Life Sciences
14.3.7 Celldex
14.3.8 Immatics Biotechnologies
